Middle East and Asia Pacific Cell and Gene Therapy Market
Overview:
Plasmid DNA is required for clinical research for genetic vaccine applications and gene therapy. High quality plasmid DNA is required for synthesis of viral vectors and mRNA, it can also be used for gene transfer in humans. A drug containing genetically modified cells like chimeric antigen receptor T cells are used along with the plasmids. In cell therapy, new living cells are transplanted to replace or repair damaged cells for the treatment of diseases like cancer. Gene therapy helps in repairing any defects in a patient’s genes for treating a particular disease. In this therapy nucleic acids like DNA or RNA consisting of vectors are transplanted in the patient’s body.
Middle East and Asia Pacific cell and gene therapy market is estimated to be valued at US$ 2,616.8 Mn in 2021 and it is expected to exhibit a CAGR of 17.3% during the forecast period.
To Get More Business Strategies Request Sample Copy of This Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/4981
Impact of COVID-19:
While the healthcare industry continues to focus on the development of COVID-19 vaccines and therapies, COVID-19 crisis had a significant impact on clinical trials in many therapy areas such as oncology, cardiovascular and others.
Healthcare industry has been more focused on the development of vaccines and therapies for the treatment of COVID-19, but the pandemic has affected the cardiovascular or oncology clinical trials. Strict restrictions during the pandemic have also affected many research programs and preclinical operations in the gene therapy sector.
Rising demand for laboratory consumables like reagents and equipment’s has been causing huge pressure on the supply chains and is expected to hinder the growth of the research and preclinical development.
Drivers:
Frequent product approvals and launches of novel gene therapies for treating rare diseases, is expected to boost growth of the Middle East and Asia Pacific Cell and Gene Therapy Market during the forecast period. For instance, in June 2017, a biotechnology company named Horama S.A gained the Orphan Drug Designation to HORARLBP1, a gene replacement therapy. HORARLBP1 can be used for the treatment of retinitis pigmentosa and retinitis punctata albescens, which are caused due to mutations in the RLBP1 gene.
Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables& Figures, Chart) @ https://www.coherentmarketinsights.com/insight/request-pdf/4981
Restraints:
Adverse reimbursement policies for cell therapy and gene therapy is expected to hinder the growth of the Middle East and Asia Pacific cell and gene therapy market during the forecast period.
Moreover, cell and gene therapies have faced major setbacks from the regulatory authorities handling the reimbursement policies, obstructing the growth of the Middle East and Asia Pacific cell and gene therapy market.
Patients suffering from acute lymphocytic leukemia can opt for Kymriah, an autologous T-cell immunotherapy, which costs around US$ 475,000 and US$ 373,000 for patients suffering from acute leukemia and large B-cell lymphoma. Government reimbursement policies can be helpful for increasing the rate of adoption of these expensive treatments.
Market Taxonomy:
By Therapy Type:
- Cell Therapy
- Stem Cells
- T Cells
- Dendritic Cells
- NK Cells
- Gene Therapy
- Germline Gene Therapy
- Somatic Gene Therapy
By Indication:
- Dermatology
- Musculoskeletal
- Oncology
- Immunology
- Cardiology & Neurology
- Others
By Technology:
- Lentiviral Vector
- Plasmid DNA
- AAV
By Region:
- Middle East
- Asia Pacific
Key players:
Key players active in the Middle East and Asia Pacific cell and gene therapy market are F. Hoffmann-La Roche AG, Biogen INC, Immuneel Therapeutics Pvt Ltd, Novartis International AG, Bluebird Bio, JCR Pharmaceuticals Co. Ltd, Regeneron Pharmaceuticals, Sanofi S.A, Pfizer, Inc, Gilead Sciences, WuxiAppTec, Gene biotherapeutics, Lonza, MeiraGTx Limited, Sibiono GeneTech Co. Ltd, uniQure N.V., Amgen Inc, Kolon TissueGene Inc, Horama S.A and Organogenesis, Inc.
Buy This Complete Business Report @ https://www.coherentmarketinsights.com/insight/buy-now/4981
Table of Contents
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Therapy Type
- Market Snippet, By Indication
- Market Snippet, By Technology
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Drivers
- Restraints
- Challenges in Cell and Gene Therapy
- Capital Intensive Process
- Opportunity
- Impact Analysis
- Adoptive T-cell’s Therapy Evolution
- Market Trends
- Regulatory Scenario
- Reimbursement Scenario
- Pipeline Analysis
- Partnership and Collaboration Scenario
- PEST Analysis
- PORTER’S Five Forces
- Epidemiology
- Company Market Share Analysis
- Drug Development Process For Cell And Gene Therapy
- Application of Plasmid DNA and Viral Vector in Cell and Gene Therapy
- Pre-clinical and Clinical Development Scenario for Cell and Gene Therapy
- Regulatory Pathway from Clinical Trials to Marketing Authorization
- List of Approved Cell and Gene Therapy Products
- List of Upcoming Cell and Gene Therapy Companies in ME and APAC Countries
- Middle East and Asia Pacific Cell and Gene Therapy Market – Impact of Coronavirus (Covid-19) Pandemic
- Economic Impact
- COVID-19 Epidemiology
- Impact on Drug Development and Clinical Trials
- Key Developments
- Middle East and Asia Pacific Cell and Gene Therapy Market, By Therapy Type, 2017 – 2028, (US$ Mn)
- Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2018 – 2028
- Segment Trends
- Cell Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Stem Cells
- T Cells
- Dendritic Cells
- NK Cells
- Gene Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Germline Gene Therapy
- Somatic Gene Therapy
- Introduction
- Middle East and Asia Pacific Cell and Gene Therapy Market, By Indication, 2017 – 2028, (US$ Mn)
- Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2018 – 2028
- Segment Trends
- Dermatology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Musculoskeletal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Oncology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Immunology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Cardiology & Neurology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Introduction
- Middle East and Asia Pacific Cell and Gene Therapy Market, By Technology, 2017 – 2028, (US$ Mn)
- Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2018 – 2028
- Segment Trends
- Lentiviral Vector
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Plasmid DNA
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- AAV
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Introduction
View Press Release: https://www.coherentmarketinsights.com/press-release/middle-east-and-asia-pacific-cell-and-gene-therapy-market-4255
About Us:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact Us:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837